China Imposes Tough New Curbs On Rep Sales Activities
Tough new rules from China’s State Council have put the country’s one million medical reps into limbo as their employers scrabble to get to grips with broad curbs on sales activities.
You may also be interested in...
China's proposal to register all medical sales reps could lead to the eventual elimination of kickbacks to physicians. Experts say it's the first step towards creating a level compliance playground for multinational and domestic drug makers.
Against a background of positive changes to regulations and policies on pharmaceutical marketing in China, US-based SciClone has accepted a buyout offer from a consortium of Chinese investors, but may relist in China in the future.
Allowing early stage Phase I studies, setting a 60-day period for IND approvals, and dropping a requirement for hospital to get certified, the China FDA proposes fundamental changes that would allow any qualified sites to file for approval to get studies rolling.